Sandoz partners with mAbxience on emicizumab biosimilar
Sandoz (SDZ.SW, SDZNY) announced a collaboration with mAbxience for a proposed emicizumab biosimilar; financial terms were not disclosed.
SW, SDZNY) said Friday it has entered into a collaboration with mAbxience for a proposed emicizumab biosimilar. Financial terms of the agreement were not disclosed.